Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 7, 2015, Pages 11683-11691

  Zhang, Yimin ^a   Yang, Jun ^b,c   Li, Hongjuan ^b   Wu, Yihua ^c   Zhang, Honghe ^c   Chen, Wenhu ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b HANGZHOU NORMAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

CA19 9; CA242; CEA; Meta analysis; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; CA 242 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

CANCER SCREENING; CHEMILUMINESCENCE IMMUNOASSAY; DATA EXTRACTION; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MEDICAL LITERATURE; META ANALYSIS; PANCREAS CANCER; PUBLICATION; QUALITY CONTROL; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 84940655696     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Maisonneuve P and Lowenfels AB. Epidemio-logy of pancreatic cancer: an update. Dig Dis 2010; 28: 645-56.
2. Bochatay L, Girardin M, Bichard P and Frossard JL. [Pancreatic cancer in 2014: screening and epidemiology]. Rev Med Suisse 2014; 10: 1582-5.
3. He XY and Yuan YZ. Advances in pancreatic cancer research: Moving towards early detection. World J Gastroenterol 2014; 20: 11241-11248.
4. Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, Maguchi H, Yanagisawa A and Tanaka M. Japan Pancreatic Cancer Re-gistry; 30th year anniversary: Japan Pancreas Society. Pancreas 2012; 41: 985-92.
5. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK and Zhao P. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005; 31: 164-9.
6. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O and Heinemann V. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010; 21: 441-7.
7. Gui JC, Yan WL and Liu XD. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Clin Exp Med 2014; 14: 225-33.
8. Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
9. Wang L, Li ZY and Zou X. The expression of CEA, CA19-9, CA242, TPA in patients with pancreatic cancer. Shandong Med J 2000; 40: 24-25.
10. Liu CM, Gui X and Duan XH. Significance of serum CA19-9 detection in the diagnosis of pancreatic cancer. Journal Of Xinjiang Medical University 2004; 27: 281-282.
11. Cui LH, Pu J, Li X and Wang XH. Combined detection of serum tumor markers in patients with pancreatic cancer. RENMIN JUNYI 2008; 51: 587-588.
12. Dong AP and Huang L. Role of combined detection of serum tumor markers in diagnosis of pancreatic cancer. Journal of Xianning Uni-versity (Medical Sciences) 2009; 23: 209-211.
13. Wang P, Cui TP, Wu JM and Sun P. Role of combined detection of serum tumor markers in diagnosis of pancreatic cancer. Central China Medical Journal 2003; 27: F003-F004.
14. Li XM, Wang LZ, Gong GF and Zhu Y. Clinical research of serum MIC-1, CA19-9, CA242 and CEA in patients with pancreatic cancer. J Clin Intern Med 2014; 31: 31-33.
15. Yang YC, Zhao YP, Liao Q, Li LJ and Han SM. Role of serum tumor markers in differential diagnosis of pancreatic occupancy. Chin J Hepatobiliary Surg 2007; 13: 361-363.
16. Chen J and Chen C. Value of combined detection of serum multi-tumor markers in diagnosis of pancreatic carcinoma. Med J Natl Defend-ing Forces Southwest China 2012; 22: 1324-1327.
17. Li XM, Hu S, Zhu Y and Gong GF. Role of serum VEGF, CA19-9, CA242 and CEA in diagnosis of pancreatic cancer. Int J Lab Med 2013; 34: 739-741.
18. Li N, Shen SQ and Liu JC. Values of CA19-9, CA242, CEA, and CA125 in diagnosis and prognosis for pancreatic cancer. Chin J Bases Clin General Surg 2011; 18: 300-304.
19. Lu C, Wang CD and Chen YL. Value of combined detection of CEA, CA19-9 and CA242 in diagnosis of pancreatic carcinoma. 2005 2005; 14: 601-602.
20. Xia F, Zheng J, Wang SG and Dong JH. Clinical significance of 12 tumor markers detection using protein biochip in the diagnosis of pancreatic carcinoma. J Digest Surg 2006; 5: 111-114.
21. Li FM. Role of combined detection of serum CEA, CA19-9 and CA242 in diagnosis of pancreatic cancer. J Radioimmunlol 2010; 23: 448-449.
22. You YQ, Lin FQ, Gong DY and Li ZP. Value of five serum tumor markers in diagnosis of pancreatic carcinoma. Int J Lab Med 2012; 33: 1266-1267.
23. Liao Q, Zhao YP, Yang YC, Li LJ, Long X and Han SM. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 2007; 6: 641-5.
24. Zhang LZ, Zhao Z and Wu B. Assay and clinical significance of serum tumor markers in diagnosis of pancreatic carcinoma. Cancer Res Clin 2008; 20: 754-756.
25. Yan H. Value of CEA, CA19-9, CA242 and Ferritin in diagnosis of pancreatic carcinoma. Journal of Changzhi Medical College 2005; 19: 290-291.
26. Gao YC, Lu HK, Liu XD and Lu Y. Complement-arity between serum tumor markers in pan-creatic carcinoma. J Shanghai Second Med University 2005; 25: 1239-1241.
27. Huang BX and Xu J. Value of serum tumor markers in diagnosis of pancreatic carcino-ma. Modern Journal of Integrated Traditional Chinese and Western Medicine 2011; 20: 873-874.
28. Zhang M. Diagnosis of pancreatic cancer through detecting 4 tumor markers in serum. Occupation and Health 2005; 21: 1007-1008.
29. Jiang A, Xiao JY and Liu XD. Value of combined detection of CA19-9, CA125, CA242 and CEA in diagnosis of pancreatic carcinoma. Shan-dong Med J 2011; 51: 43-44.
30. Deeks JJ, Macaskill P and Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-93.
31. Zhang LZ, Gong YF and Tu ZX. Quantitative determination of serum levels of CA242 in patients with pancreatic cancer and its significance. Chin J Pancreatol 2002; 2: 20-21.